Your browser doesn't support javascript.
loading
The long-term consequences of Corona Virus Disease 2019 patients receiving Chinese herbal medicine treatments in acute phase: A protocol for systematic review and meta-analysis.
Sun, Yi-Ming; Liu, Jia-Yan; Sun, Ran; Zhang, Jie; Xiao, Meng-Lu; Li, Gui-Ping.
Afiliação
  • Sun YM; Chengdu Eighth People's Hospital (Geriatric Hospital of Chengdu Medical College), Chengdu, China.
  • Liu JY; Tianjin Xiangyang Road Community Health Service Center, China.
  • Sun R; Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • Zhang J; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  • Xiao ML; Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • Li GP; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Medicine (Baltimore) ; 100(29): e26677, 2021 Jul 23.
Article em En | MEDLINE | ID: mdl-34398036
ABSTRACT

BACKGROUND:

In December 2019, the first case of Corona Virus Disease 2019 (COVID-19) associated with severe acute respiratory syndrome coronavirus-2 viral infection was described in Wuhan. Similar to SARS in 2003, COVID-19 also had a lasting impact. Approximately 76% of patients discharged after hospitalization for COVID-19 had neurological manifestations which could persist for 6 months, and some long-term consequences such as the gradual loss of lung function due to pulmonary interstitial fibrosis could have comprehensive effects on daily quality of life for people who were initially believed to have recovered from COVID-19. METHODS AND

ANALYSIS:

Our comprehensive search strategy developed in consultation with a research librarian. We will search these following electronic databases PubMed, Cochrane Library, Web of Science, ScienceDirect, Scopus, Google Scholar, Embase, ProQuest, China Science and Technology Journal Database (VIP), China National Knowledge Infrastructure, WANFANG DATA, WHO covid-19 website, and Centers for Disease Control and the Prevention COVID-19 websites of the United States and China. The bias of publication will be confirmed via the P value of Egger test. The quality of studies will be evaluated by the Newcastle-Ottawa Scale. ETHICS AND DISSEMINATION There are no ethical considerations associated with this study protocol for this systematic review which mainly focuses on the examination of secondary data. On completion of this analysis, we will prepare a manuscript for publication in a peer-reviewed medical journal. PROSPERO REGISTRATION NUMBER CRD42021258711.
Assuntos

Texto completo: 1 Eixos temáticos: Pesquisa_clinica Base de dados: MEDLINE Assunto principal: Medicamentos de Ervas Chinesas / Tratamento Farmacológico da COVID-19 Tipo de estudo: Diagnostic_studies / Guideline / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Eixos temáticos: Pesquisa_clinica Base de dados: MEDLINE Assunto principal: Medicamentos de Ervas Chinesas / Tratamento Farmacológico da COVID-19 Tipo de estudo: Diagnostic_studies / Guideline / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article